A UK statistician tells the Guardian that non-invasive prenatal screening for trisomies won't increase the number of terminations.
By offering NIPT as a secondary screening test, the UK hopes to reduce the number of invasive diagnostic tests and associated miscarriages.
The contract was awarded by the UK's NHS Blood and Transplant, which is responsible for promoting and overseeing organ and blood donation.
St. George's University Hospitals NHS Foundation Trust, which has been offering NIPT since last year, plans to double its capacity by the third quarter.
The recommendation calls for NIPT to be initially offered to women deemed at high risk for trisomy 21, 13, or 18 after the initial screening test.
Motherboard looks into the UK's 100,000 Genomes Project.
The innovation hub will be fully operational by end of 2016 or in early 2017 and will be headquartered in the Cambridge Biomedical Campus.
Under the three-year project award, Premaitha and St George's plan to establish a UK Centre of Excellence for Prenatal Screening.
The NICE recommendation specifies the use of Oncotype DX for intermediate risk patients for whom doctors are unclear whether to prescribe chemotherapy.
During its second quarter earnings call, Myriad officials detailed the market prospects for its tumor and germline BRACAnalysic CDx tests.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.